A Clinical Trial of Oral Midazolam Plus Oral Ketamine for Sedation During Laceration Repair
Primary Purpose
Lacertaions
Status
Unknown status
Phase
Phase 4
Locations
Israel
Study Type
Interventional
Intervention
Ketamine
Normal Saline
Sponsored by
About this trial
This is an interventional treatment trial for Lacertaions
Eligibility Criteria
Inclusion Criteria:
- Age: 1 years - 10 years
- Any child with laceration requiring sedation
Exclusion Criteria:
- Major trauma
- Closed head injury associated with loss of consciousness
- Abnormal neurologic examination in a previously normal child
- Significant developmental delay or baseline neurological deficit
- A patient with seizures
- Elevated intra-cranial pressure
- Hypersensitivity to midazolam or ketamine
- Hypertension
- Hyperthyroidism or a patient receiving thyroid replacement
- alcohol intoxication or a history of alcohol abuse
- Acute or chronic respiratory, cardiac, renal or hepatic abnormalities
- Glaucoma
- Known psychiatric disease
- ASA score of more than 2
- Informed consent cannot be obtained from legal guardian
Sites / Locations
- Pediatric Emergency DepartmentRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Ketamine
Placebo
Arm Description
Oral Ketamine in addition to oral midazolam
Normal saline (placebo) in addition to oral midazolam
Outcomes
Primary Outcome Measures
Pain score: Visual analog score (VAS)- by parent
Secondary Outcome Measures
Pain score: Visual analog score (VAS)- by a physician
Full Information
NCT ID
NCT01470157
First Posted
September 19, 2011
Last Updated
November 9, 2011
Sponsor
Assaf-Harofeh Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT01470157
Brief Title
A Clinical Trial of Oral Midazolam Plus Oral Ketamine for Sedation During Laceration Repair
Official Title
A Randomized, Clinical Trial of Oral Midazolam Plus Placebo Versus Oral Midazolam Plus Oral Ketamine for Sedation During Laceration Repair
Study Type
Interventional
2. Study Status
Record Verification Date
November 2011
Overall Recruitment Status
Unknown status
Study Start Date
July 2011 (undefined)
Primary Completion Date
March 2012 (Anticipated)
Study Completion Date
July 2012 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Assaf-Harofeh Medical Center
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Background: Sedation is often needed for young children undergoing minor procedures in the emergency department (ED). Oral midazolam is one of the most commonly used regimens for children undergoing laceration repair but its sedative efficacy was shown to be suboptimal. In a few studies oral ketamine has been used successfully for procedural sedation as well. The efficacy of using a combination of oral midazolam and oral ketamine for procedural sedation has been studied only for invasive procedures in children with malignancies. No randomized controedll studies were performed using this sedative combination in children requiring laceration repair. Objectives: To determine the efficacy of adding oral ketamine to oral midazolam for procedural sedation in children requiring laceration repair compares to oral midazolam plus placebo. Design: A randomized, double blind, placebo-controlled study. Setting: Pediatric Emergency Department. Participants: Children 1 to 10 years with laceration requiring sedation. Interventions: Eligible patients will be randomly assigned to one of two treatment groups: oral midazolam plus oral placebo group and oral midazolam plus oral ketamine group. Both groups will be given the same volume of medications. Midazolam will be given orally in a dose of 0.5 mg/kg (max.-15 mg) with placebo or 0.5 mg/kg (max.- 15 mg) with oral ketamine in a dose of 5 mg/kg. The medical staff will be blinded to the treatment given. Patient monitoring will be conducted according to the American Academy of Pediatrics (APP) and the Israeli health ministry guidelines for monitoring and management of pediatric patients during and after sedation for diagnostic and therapeutic procedures. Main outcome measures: Pain score: Visual Analog Score (VAS) - by parent. Data analysis: Descriptive statistics will be used to describe the study population. Data will be analyzed using t- tests for continuous data and Fisher exact test for categorical data.
Key words: sedation, children, ketamine, midazolam, emergency department.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lacertaions
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Ketamine
Arm Type
Experimental
Arm Description
Oral Ketamine in addition to oral midazolam
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Normal saline (placebo) in addition to oral midazolam
Intervention Type
Drug
Intervention Name(s)
Ketamine
Intervention Description
5mg/kg as oral suspension
Intervention Type
Drug
Intervention Name(s)
Normal Saline
Intervention Description
Normal Saline (placebo) in addition to Midazolam 0.5mg/kg as oral suspension
Primary Outcome Measure Information:
Title
Pain score: Visual analog score (VAS)- by parent
Time Frame
participants will be followed for the duration of hospital stay, an expected average of 3 hours
Secondary Outcome Measure Information:
Title
Pain score: Visual analog score (VAS)- by a physician
Time Frame
while in the ED for about 3 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
10 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age: 1 years - 10 years
Any child with laceration requiring sedation
Exclusion Criteria:
Major trauma
Closed head injury associated with loss of consciousness
Abnormal neurologic examination in a previously normal child
Significant developmental delay or baseline neurological deficit
A patient with seizures
Elevated intra-cranial pressure
Hypersensitivity to midazolam or ketamine
Hypertension
Hyperthyroidism or a patient receiving thyroid replacement
alcohol intoxication or a history of alcohol abuse
Acute or chronic respiratory, cardiac, renal or hepatic abnormalities
Glaucoma
Known psychiatric disease
ASA score of more than 2
Informed consent cannot be obtained from legal guardian
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Shiri Barkan, MD
Phone
972 544385404
Email
shiri_barkan@yahoo.com
Facility Information:
Facility Name
Pediatric Emergency Department
City
Assaf Harofeh, Zerifin
ZIP/Postal Code
70300
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shiri Barkan, MD
Phone
972 544385404
Email
shiri_barkan@yahoo.com
First Name & Middle Initial & Last Name & Degree
Shiri Barkan, MD
12. IPD Sharing Statement
Citations:
PubMed Identifier
23686730
Citation
Barkan S, Breitbart R, Brenner-Zada G, Feldon M, Assa A, Toledano M, Berkovitch S, Shavit I, Kozer E. A double-blind, randomised, placebo-controlled trial of oral midazolam plus oral ketamine for sedation of children during laceration repair. Emerg Med J. 2014 Aug;31(8):649-53. doi: 10.1136/emermed-2012-202189. Epub 2013 May 18.
Results Reference
derived
Learn more about this trial
A Clinical Trial of Oral Midazolam Plus Oral Ketamine for Sedation During Laceration Repair
We'll reach out to this number within 24 hrs